RIGI and cancer: In summary, our results demonstrate that SLR14, a synthetic RIG-I agonist, induces a potent in vivo antitumor effect in immunogenic or poorly immunogenic cancers by activating the cytosolic RIG-I signaling pathway in different cell populations.